Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Retained Earnings (2023 - 2025)

CG Oncology (CGON) has disclosed Retained Earnings for 3 consecutive years, with -$379.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 73.87% year-over-year to -$379.0 million, compared with a TTM value of -$379.0 million through Dec 2025, down 73.87%, and an annual FY2025 reading of -$379.0 million, down 73.87% over the prior year.
  • Retained Earnings was -$379.0 million for Q4 2025 at CG Oncology, down from -$337.7 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$129.9 million in Q4 2023 and bottomed at -$379.0 million in Q4 2025.
  • Average Retained Earnings over 3 years is -$234.4 million, with a median of -$218.0 million recorded in 2024.
  • The sharpest move saw Retained Earnings crashed 67.75% in 2024, then plummeted 81.36% in 2025.
  • Year by year, Retained Earnings stood at -$129.9 million in 2023, then plummeted by 67.75% to -$218.0 million in 2024, then plummeted by 73.87% to -$379.0 million in 2025.
  • Business Quant data shows Retained Earnings for CGON at -$379.0 million in Q4 2025, -$337.7 million in Q3 2025, and -$293.9 million in Q2 2025.